Metastasis—the spread of cancer to distant organs—is responsible for most cancer deaths.
Current adjuvant therapy is based on prognostic indicators that stratify patients into defined
risk groups. However, some patients believed to have a good prognosis nonetheless
develop metastases, in some cases many years after apparently successful treatment of
their primary cancer. This period of clinical dormancy leads to many questions about how
best to manage patients, including how to better assign risk of late recurrence, how long to …